Scholar Rock Holding Corporation reported a net loss of $91.0 million for the quarter ended December 31 2025, a 37% increase from the $66.5 million loss recorded in the same period a year earlier. The company’s earnings per share for the quarter were $-0.88, beating the consensus estimate of $-0.91 by $0.03 and later revised to $-0.76 after an amendment, which still surpassed the estimate by $0.15. Revenue for the quarter and the full year was $0, in line with analyst expectations of zero revenue for a clinical‑stage biopharmaceutical that has not yet received regulatory approval for its lead product.
The company’s operating expenses rose to $91.9 million in Q4 2025, a decrease from the $103.6 million reported in the original release. The expense increase was driven largely by higher research and development costs of $208.44 million and general and administrative expenses of $176.205 million for the full year. Non‑cash stock‑based compensation accounted for $19.4 million of the operating expenses, as noted by CFO Vikas Sinha. The company’s cash, cash equivalents, and marketable securities stood at $367.6 million as of December 31 2025, providing a runway into 2027.
Management emphasized progress on its flagship product, apitegromab. CEO David L. Hallal said, "We are ready to resubmit our apitegromab BLA following successful reinspection of the site by the FDA," underscoring the company’s focus on resolving manufacturing issues that led to a Complete Response Letter in September 2025. Hallal also added, "Scholar Rock is poised for a transformative year in 2026," highlighting the anticipated U.S. launch of the therapy. CFO Sinha noted, "We ended 2025 with $368 million in cash and cash equivalents," and announced a new debt facility of up to $550 million with Blue Owl Capital, providing additional financial flexibility for commercialization and pipeline development.
The earnings beat, driven by disciplined cost management and a lower-than‑expected loss per share, signals that the company is controlling its operating expenses while investing heavily in commercial readiness. The zero revenue figure confirms that the company remains in the pre‑commercial phase, and the substantial cash reserves combined with the new debt facility position Scholar Rock to navigate the regulatory process and prepare for a potential launch of apitegromab in 2026. The company’s focus on resolving manufacturing issues and securing a second fill‑finish facility aligns with its strategy to capture the $5 billion SMA market once regulatory approval is achieved.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.